NHS England Approves New Life-Prolonging Drug for Ovarian Cancer
Life-prolonging drug for advanced ovarian cancer gets go-ahead in England
Image: The Guardian
NHS England has approved mirvetuximab soravtansine, the first new treatment for resistant ovarian cancer in over 20 years, offering hope to up to 400 women annually. This drug targets specific cancer cells, potentially extending survival by four months and improving quality of life.
- 01Mirvetuximab soravtansine, branded as Elahere, is designed for patients with FRα-positive platinum-resistant ovarian cancer.
- 02The drug is administered via drip every three weeks and has shown to delay cancer progression significantly.
- 03Clinical trials indicated that 37% of patients experienced a reduction in tumor size by at least 30%.
- 04This approval marks a significant milestone in treatment options for advanced ovarian cancer, which affects over 300,000 women annually worldwide.
- 05Experts emphasize the drug's potential to improve the quality of life for patients and their families.
Advertisement
In-Article Ad
NHS England has approved the use of mirvetuximab soravtansine, a groundbreaking treatment for advanced ovarian cancer, marking the first new drug for resistant cases in over two decades. This approval is particularly significant for patients with folate receptor-alpha-positive platinum-resistant epithelial cancers, who have faced limited treatment options. The drug, also known as Elahere, is administered via drip every three weeks and has been shown to delay cancer progression and extend survival by an average of four months compared to traditional chemotherapy. Clinical trials revealed that 37% of patients experienced a significant reduction in tumor size, highlighting its efficacy. With the potential to benefit up to 400 women annually in England, this decision is seen as a major advancement in cancer treatment. Experts and advocacy groups have expressed optimism, stating that this treatment offers renewed hope for patients and their families during a challenging time.
Advertisement
In-Article Ad
The approval of mirvetuximab soravtansine is expected to significantly enhance treatment options for women with advanced ovarian cancer in England.
Advertisement
In-Article Ad
Reader Poll
What do you think about the new treatment for ovarian cancer?
Connecting to poll...
More about NHS England
NHS Approves New Targeted Treatment for Ovarian Cancer After 20 Years
Evening Standard • Jun 4, 2026
NHS Approves New Ovarian Cancer Treatment, Benefiting Hundreds of Women
The Independent • Jun 4, 2026
Urgent Investigation Called for Deaths Linked to Black Market Weight Loss Injections
The Independent • Jun 3, 2026
Read the original article
Visit the source for the complete story.